Scrutinizing Primary Endpoints in ALS Clinical Trials: ALSFRS-R, Survival or a Composite?
Speaker
Prof. dr. Leonard van den Berg
Neurologist
Prof. dr. Leonard van den Berg is a neurologist at University Medical Centre (UMC) Utrecht and ALS Centrum. He is experienced in conducting global ALS trials, established the prominent TRICALS site network, and is chair of the European Network for the Cure of ALS.
During this webinar, Leonard van den Berg, MD, PhD (Chairman TRICALS | UMC Utrecht, NL) and Ruben van Eijk MD, PhD (Lead Statistician TRICALS | UMC Utrecht, NL) will discuss Primary endpoints in ALS clinical trials, differences in regulatory requirement of the EMA and FDA and statistical considerations.
They touched upon:
- Primary endpoints in ALS clinical trials
- Regulatory requirements: differences between EMA and FDA
- Statistical considerations for ALSFRS-R, survival and composites
Followed by a Q&A session.
Speakers: Prof. Leonard van den Berg, MD, PhD & Dr. Ruben van Eijk, MD, PhD
Related webinars
Webinar – Improving ALS Trial Delivery Through Insights from Patient and Industry Experience
On January 19, at 16.30 CET, we will present the webinar: Improving ALS Trial Delivery Through Insights from Patient and Industry ExperienceWhat You’ll LearnPatient- and Industry-Informed Insights Top patient-experience pitfalls obs...
Webinar – Boosting patient enrolment and retention in clinical trials: Expert Insights & Tips
On June 30, at 16.00 CEST, we will present the webinar: Boosting patient enrolment and retention in clinical trials: Expert Insights & TipsJoin us for an interactive discussion with experts who will draw upon recent cardiology and neurolog...
Webinar: The Role of EEG in Dementia Trials
How early can you detect whether a treatment is working in dementia trials, and what if you didn’t have to wait for traditional endpoints? Electroencephalography (EEG) is gaining momentum as a powerful tool to capture real-time changes in brain...